Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (35)
Ajay Duseja, S.P. Singh, Arka De, Kaushal Madan, Padaki Nagaraja Rao, Akash Shukla, Gourdas Choudhuri, Sanjiv Saigal, Shalimar, Anil Arora, Anil C. Anand, Ashim Das, Ashish Kumar, Chundamannil E. Eapen, Krishnadas Devadas, Kotacherry T. Shenoy, Manas Panigrahi, Manav Wadhawan, Manish Rathi, Manoj Kumar, Narendra S. Choudhary, Neeraj Saraf, Preetam Nath, Sanjib Kar, Seema Alam, Samir Shah, Sandeep Nijhawan, Subrat K. Acharya, Vinayak Aggarwal, Vivek A. Saraswat & Yogesh K. Chawla. (2023) Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD). Journal of Clinical and Experimental Hepatology 13:2, pages 273-302.
Crossref
Crossref
Lina Gruneau, Mattias Ekstedt, Stergios Kechagias & Martin Henriksson. (2023) Disease Progression Modeling for Economic Evaluation in Nonalcoholic Fatty Liver Disease—A Systematic Review. Clinical Gastroenterology and Hepatology 21:2, pages 283-298.
Crossref
Crossref
Marco Arrese, Juan P. Arab, Francisco Barrera, Benedikt Kaufmann, Luca Valenti & Ariel E. Feldstein. (2021) Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. Seminars in Liver Disease 41:04, pages 421-434.
Crossref
Crossref
Abraham Stijn Meijnikman, Hilde Herrema, Torsten Pascal Marcel Scheithauer, Jeffrey Kroon, Max Nieuwdorp & Albert Kornelis Groen. (2021) Evaluating causality of cellular senescence in non-alcoholic fatty liver disease. JHEP Reports 3:4, pages 100301.
Crossref
Crossref
Elizabeth M. Brunt, David E. Kleiner, Danielle H. Carpenter, Mary Rinella, Stephen A. Harrison, Rohit Loomba, Zobair Younossi, Brent A. Neuschwander‐Tetri & Arun J. Sanyal. (2021) NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology 73:5, pages 2028-2038.
Crossref
Crossref
Donald J. AbrahamRalf Glatthar & Robert H. Arch. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
71
.
Ariel Sasson, Eva Kristoferson, Rogerio Batista, John A. McClung, Nader G. Abraham & Stephen J. Peterson. (2021) The pivotal role of heme Oxygenase-1 in reversing the pathophysiology and systemic complications of NAFLD. Archives of Biochemistry and Biophysics 697, pages 108679.
Crossref
Crossref
Rommel Zambrano-Huailla, Laura Guedes, Jose Tadeu Stefano, Arthur A. Arrais de Souza, Sebastián Marciano, Erika Yvamoto, Matheus Truccolo Michalczuk, Denise Siqueira Vanni, Hernan Rodriguez, Flair Jose Carrilho, Mario Reis Alvares-da-Silva, Adrian Gadano, Marco Arrese, Adelina Lozano Miranda & Claudia P. Oliveira. (2020) Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population. Annals of Hepatology 19:6, pages 622-626.
Crossref
Crossref
Fabio Nascimbeni, Pierre Bedossa, Larysa Fedchuk, Raluca Pais, Frédéric Charlotte, Pascal Lebray, Thierry Poynard & Vlad Ratziu. (2020) Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. Journal of Hepatology 72:5, pages 828-838.
Crossref
Crossref
Arka De & Ajay Duseja. (2020) Natural History of Simple Steatosis or Nonalcoholic Fatty Liver. Journal of Clinical and Experimental Hepatology 10:3, pages 255-262.
Crossref
Crossref
Zachary H. Henry & Curtis K. Argo. (2020) How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis. Gastroenterology Clinics of North America 49:1, pages 45-62.
Crossref
Crossref
Nabil Noureddin, Ma Ai Thanda Han, Naim Alkhouri & Mazen Noureddin. (2020) Accounting for the Placebo Effect and Optimizing Outcomes in Clinical Trials of Nonalcoholic Steatohepatitis (NASH). Current Hepatology Reports 19:1, pages 63-69.
Crossref
Crossref
Mohamed MostafaAmrou AbdelkaderJohn J. EvansCatherine E. HagenChristopher P. Hartley. (2019) Fatty Liver Disease: A Practical Approach. Archives of Pathology & Laboratory Medicine 144:1, pages 62-70.
Crossref
Crossref
Rish K. Pai. (2019) NAFLD Histology: a Critical Review and Comparison of Scoring Systems. Current Hepatology Reports 18:4, pages 473-481.
Crossref
Crossref
David E. Kleiner, Elizabeth M. Brunt, Laura A. Wilson, Cynthia Behling, Cynthia Guy, Melissa Contos, Oscar Cummings, Matthew Yeh, Ryan Gill, Naga Chalasani, Brent A. Neuschwander-Tetri, Anna Mae Diehl, Srinivasan Dasarathy, Norah Terrault, Kris Kowdley, Rohit Loomba, Patricia Belt, James Tonascia, Joel E. Lavine & Arun J. Sanyal. (2019) Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Network Open 2:10, pages e1912565.
Crossref
Crossref
Arun J. Sanyal. (2019) Past, present and future perspectives in nonalcoholic fatty liver disease. Nature Reviews Gastroenterology & Hepatology 16:6, pages 377-386.
Crossref
Crossref
Safa Hoodeshenas, Meng Yin & Sudhakar Kundapur Venkatesh. (2018) Magnetic Resonance Elastography of Liver. Topics in Magnetic Resonance Imaging 27:5, pages 319-333.
Crossref
Crossref
Vlad Ratziu. (2018) A critical review of endpoints for non-cirrhotic NASH therapeutic trials. Journal of Hepatology 68:2, pages 353-361.
Crossref
Crossref
Quentin M. Anstee & Christopher P. Day. 2018. Zakim and Boyer's Hepatology. Zakim and Boyer's Hepatology
391
405.e3
.
Amedeo Lonardo, Fabio Nascimbeni, Mauro Maurantonio, Alessandra Marrazzo, Luca Rinaldi & Luigi Elio Adinolfi. (2017) Nonalcoholic fatty liver disease: Evolving paradigms. World Journal of Gastroenterology 23:36, pages 6571-6592.
Crossref
Crossref
Stephen M. Smith, Martha M. Yearsley & Douglas Levin. (2017) Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology 15:9, pages 1479.
Crossref
Crossref
Yousef Fazel, Aaron B. Koenig, Mehmet Sayiner, Zachary D. Goodman & Zobair M. Younossi. (2016) Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism 65:8, pages 1017-1025.
Crossref
Crossref
Elena Buzzetti, Massimo Pinzani & Emmanuel A. Tsochatzis. (2016) The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65:8, pages 1038-1048.
Crossref
Crossref
Zachary H. Henry, Stephen H. Caldwell & Curtis K. Argo. (2016) Nonalcoholic Fatty Liver Disease: Prognosis and Progression of Disease. Current Hepatology Reports 15:2, pages 117-124.
Crossref
Crossref
Vlad Ratziu, Stephen A. Harrison, Sven Francque, Pierre Bedossa, Philippe Lehert, Lawrence Serfaty, Manuel Romero-Gomez, Jérôme Boursier, Manal Abdelmalek, Steve Caldwell, Joost Drenth, Quentin M. Anstee, Dean Hum, Remy Hanf, Alice Roudot, Sophie Megnien, Bart Staels, Arun Sanyal, P. Mathurin, J. Gournay, E. Nguyen-Khac, V. De Ledinghen, D. Larrey, A. Tran, M. Bourliere, M. Maynard-Muet, T. Asselah, J. Henrion, F. Nevens, D. Cassiman, A. Geerts, C. Moreno, U.H. Beuers, P.R. Galle, U. Spengler, E. Bugianesi, A. Craxi, M. Angelico, S. Fargion, M. Voiculescu, L. Gheorghe, L. Preotescu, J. Caballeria, R.J. Andrade, J. Crespo, J.L. Callera, A. Ala, G. Aithal, G. Abouda, V. Luketic, M.A. Huang, S. Gordon, P. Pockros, F. Poordad, N. Shores, M.W. Moehlen, K. Bambha, V. Clark, S. Satapathy, S. Parekh, R.K. Reddy, M.Y. Sheikh, G. Szabo, J. Vierling, T. Foster, G. Umpierrez, C. Chang, T. Box & J. Gallegos-Orozco. (2016) Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology 150:5, pages 1147-1159.e5.
Crossref
Crossref
Vlad Ratziu. 2016. Clinical Dilemmas in Non‐Alcoholic Fatty Liver Disease. Clinical Dilemmas in Non‐Alcoholic Fatty Liver Disease
111
123
.
Arun J. Sanyal, Brent A. Neuschwander-Tetri & James Tonascia. (2016) End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease. Gastroenterology 150:1, pages 11-13.
Crossref
Crossref
Mattias Ekstedt, Hannes Hagström, Patrik Nasr, Mats Fredrikson, Per Stål, Stergios Kechagias & Rolf Hultcrantz. (2015) Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up. Hepatology 61:5, pages 1547-1554.
Crossref
Crossref
Vlad Ratziu, Zachary Goodman & Arun Sanyal. (2015) Current efforts and trends in the treatment of NASH. Journal of Hepatology 62:1, pages S65-S75.
Crossref
Crossref
Vlad Ratziu. (2015) Starting the battle to control non-alcoholic steatohepatitis. The Lancet 385:9972, pages 922-924.
Crossref
Crossref
Per Stål. (2015) Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. World Journal of Gastroenterology 21:39, pages 11077.
Crossref
Crossref
Cory M. Fielding & Paul Angulo. (2014) Hepatic Steatosis and Steatohepatitis: Are they Really Two Distinct Entities?. Current Hepatology Reports 13:2, pages 151-158.
Crossref
Crossref
J K Dyson, S McPherson & Q M Anstee. (2014) Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. Postgraduate Medical Journal 90:1063, pages 254-266.
Crossref
Crossref
Mariana Verdelho Machado. (2014) Non-alcoholic fatty liver disease: What the clinician needs to know. World Journal of Gastroenterology 20:36, pages 12956.
Crossref
Crossref
J K Dyson, S McPherson & Q M Anstee. (2013) Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. Journal of Clinical Pathology 66:12, pages 1033-1045.
Crossref
Crossref